- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT05363722
Clinical Study on Efficacy and Safety of IBI310, Bevacizumab Combined With Sintilimab in Advanced HCC
A Single-Arm, Multicenter Phase Ib Study on the Efficacy and Safety of IBI310 in Combination With Bevacizumab and Sintilimab for First-Line Treatment of Advanced Hepatocellular Carcinoma
This is a single-arm, multicenter phase Ib study to evaluate the effectiveness and safety of IBI310, bevacizumab combined with sintilimab in patients with locally advanced or metastatic HCC who have not previously received systemic therapy, are unsuitable for radical surgical resection or local treatment, or have progressive disease after surgical resection or local treatment.
Обзор исследования
Статус
Условия
Вмешательство/лечение
Подробное описание
This is a single-arm, multicenter phase Ib study evaluating the safety and efficacy of IBI310 combined with sintilimab and bevacizumab in advanced hepatocellular carcinoma. Patients will receive IBI310 1.0 mg/kg IV on day 1 every 6 weeks plus sintilimab 200 mg IV and bevacizumab 15 mg/kg IV on day 1 every 3 weeks. Approximately 50 patients are planned. After the first 6-10 patients are treated, the Safety Monitoring Committee (SMC) will assess safety in this subgroup and determine whether enrollment should continue.
Treatment will continue until disease progression, intolerable toxicity, initiation of new antitumor therapy, withdrawal of informed consent, loss to follow-up, death, or other protocol-defined discontinuation, whichever occurs first, for a maximum of 24 months. Patients with initial investigator-assessed radiographic progression per RECIST v1.1 may continue study treatment if clinically stable, likely to benefit, and willing to continue; tumor response will then be assessed by iRECIST until no further benefit per investigator, intolerable toxicity, new antitumor therapy, consent withdrawal, loss to follow-up, or maximum treatment duration, whichever occurs first.
Тип исследования
Регистрация (Оцененный)
Фаза
- Фаза 1
Контакты и местонахождение
Контакты исследования
- Имя: Chengfeng Liu
- Номер телефона: +86 15201927474
- Электронная почта: liu.chengfeng@zs-hospital.sh.cn
Места учебы
-
-
-
Shanghai, Китай
- Рекрутинг
- Zhongshan Hospital, Fudan University
-
Контакт:
- Chengfeng Liu
- Номер телефона: +86 15201927474
- Электронная почта: liu.chengfeng@zs-hospital.sh.cn
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
- Histologically/cytologically confirmed hepatocellular carcinoma, or meeting the clinical diagnostic criteria for hepatocellular carcinoma ;
- Aged ≥18 years,≤75 years;
- ECOG performance status score of 0 or 1 point;
- Barcelona Clinic Liver Cancer (BCLC) stage C, or Stage B not suitable for radical surgery and/or local treatment;
- No systemic antitumor treatment for hepatocellular carcinoma before the first administration;
- At least 1 measurable lesion according to the Response Evaluation Criteria in Solid Tumors Version 1.1(RECIST V1.1), or measurable lesion with definite progression after local treatment (based on RECIST V1.1 criteria), at least 4 weeks before enrollment (for those who received local radioisotope therapy, at least 3 months)
- Child-Pugh Class A or B(≤7);
- Adequate organ and bone marrow function.
- Expected life time is over 12 weeks.
- Take effective contraceptive measures
- Willing to attend the study and having given the ICF
Exclusion Criteria:
- Known fibrolamellar HCC, sarcomatoid HCC, mixed cholangiocarcinoma and HCC
- History of hepatic encephalopathy or liver transplantation
- Pleural, ascites, and pericardial effusion with clinical symptoms requiring drainage
- HBV-DNA>2000 IU/ML or 10^4 copies/ml;Untreated positive HCV-RNA;HbsAg and anti-HCV antibody were both positive
- History of GI bleeding within 6 months, or severe (G3) varices at endoscopy within 3 months
- Arteriovenous embolism within 6 months
- The tumor thrombus involved both main and branch portal veins, main portal veins and mesenteric veins or inferior vena cava.
- Antiplatelet drugs were administered for 10 days for therapeutic purposes 2 weeks before administration
- Uncontrolled hypertension
- Unrecovered AE(>CTCAE grade 1) due to previous treatment
- Heart failure (NYHA Classification III-IV), or poorly controlled arrhythmias
- History of gastrointestinal perforation, fistula, intestinal obstruction, extensive bowel resection, Crohn's disease, ulcerative colitis, or chronic diarrhea
- With lung fibrosis, interstitial lung disease, pneumoconiosis, drug-associated pneumonia and serious impairment in lung function
- Active tuberculosis
- Infected with HIV or syphilis
- Severe infections that are active or clinically poorly controlled
- Use of immunosuppressive drugs within 4 weeks prior to initial dosing
- Receipt of live attenuated vaccine within 4 weeks prior to randomization
- Significant traumatic injury or major surgical procedure within 28 days prior to randomization
- Other conditions that the investigator judged inappropriate for inclusion
- Prior immunotherapy or targeted therapy
- Treatment of Traditional Chinese medicine with anti-tumor indications or drugs with immunomodulatory effects whitin 2 weeks
- Pregnant or breast-feeding women
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Н/Д
- Интервенционная модель: Одногрупповое задание
- Маскировка: Нет (открытая этикетка)
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Экспериментальный: Single-Arm
IBI310 1mg/kg IV d1 Q6W, sintilimab 200mg IV d1 Q3W, combined with bevacizumab 15mg/kg IV d1,Q3W |
IBI310 1mg/kg IV d1 Q6W sintilimab 200 mg IV d1 Q3W
Другие имена:
bevacizumab 15 mg/kg IV d1,Q3W
Другие имена:
|
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Treatment Emergent Adverse Event, TEAE
Временное ограничение: Any emergent adverse event from first dose through study completion, up to 2 years.
|
Safety |
Any emergent adverse event from first dose through study completion, up to 2 years.
|
|
Severe Adverse Event, SAE
Временное ограничение: Any severe adverse event from first dose through study completion, up to 2 years.
|
Safety |
Any severe adverse event from first dose through study completion, up to 2 years.
|
|
Objective response rate (ORR)
Временное ограничение: The proportion of patients with complete response or partial response, through study completion, up to 2 years
|
efficacy |
The proportion of patients with complete response or partial response, through study completion, up to 2 years
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Duration of Response(DOR)according to RECIST V1.1 criteria
Временное ограничение: From the date of first documented response(CR/PR) until the date of progression or death, up to 48 months
|
efficacy |
From the date of first documented response(CR/PR) until the date of progression or death, up to 48 months
|
|
Duration of Response(DOR)according to mRECIST criteria
Временное ограничение: From the date of first documented response(CR/PR) until the date of progression or death, up to 48 months
|
efficacy |
From the date of first documented response(CR/PR) until the date of progression or death, up to 48 months
|
|
Disease Control Rate(DCR) according to RECIST V1.1 criteria
Временное ограничение: The percentage of patients whose therapeutic intervention has led to a complete response, partial response, or stable disease, through study completion, up to 2 years
|
efficacy |
The percentage of patients whose therapeutic intervention has led to a complete response, partial response, or stable disease, through study completion, up to 2 years
|
|
Disease Control Rate(DCR) according to mRECIST criteria
Временное ограничение: The percentage of patients whose therapeutic intervention has led to a complete response, partial response, or stable disease, through study completion, up tp 2 years
|
efficacy |
The percentage of patients whose therapeutic intervention has led to a complete response, partial response, or stable disease, through study completion, up tp 2 years
|
|
Objective response rate (ORR) according to mRECIST criteria
Временное ограничение: The proportion of patients with complete response or partial response, through study completion, an average of 2 years
|
efficacy |
The proportion of patients with complete response or partial response, through study completion, an average of 2 years
|
|
Progresison Free Survival(PFS)according to RECIST V1.1 criteria
Временное ограничение: From date of randomization until the date of the first documented progression or date of death from any cause, whichever comes first, assessed up to 48 months
|
efficacy |
From date of randomization until the date of the first documented progression or date of death from any cause, whichever comes first, assessed up to 48 months
|
|
Progresison Free Survival(PFS)according to mRECIST criteria
Временное ограничение: From date of randomization until the date of the first documented progression or date of death from any cause, whichever comes first, assessed up to 48 months
|
efficacy |
From date of randomization until the date of the first documented progression or date of death from any cause, whichever comes first, assessed up to 48 months
|
|
Overall survival (OS)
Временное ограничение: From the date of randomization until death from any cause, assessed up to 48 months.
|
efficacy |
From the date of randomization until death from any cause, assessed up to 48 months.
|
Соавторы и исследователи
Спонсор
Следователи
- Главный следователь: Zhenggang Ren, Shanghai Zhongshan Hospital
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Оцененный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Дополнительные соответствующие термины MeSH
- Новообразования по локализации
- Новообразования
- Новообразования по гистологическому типу
- Новообразования пищеварительной системы
- Заболевания пищеварительной системы
- Заболевания печени
- Новообразования железистые и эпителиальные
- Аденокарцинома
- Новообразования печени
- Карцинома
- Карцинома, гепатоцеллюлярная
- Аминокислоты, пептиды и белки
- Белки
- Антитела, моноклональные, гуманизированные
- Антитела, моноклональные
- Антитела
- Иммуноглобулины
- Иммунопротеины
- Белки крови
- Сывороточные глобулины
- Глобулины
- Бевацизумаб
- Синтилимаб
Другие идентификационные номера исследования
- CIBI310Y001
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .